Beamr video compression achieves up to 50% improvement for AVs
DUBLIN - Investment firm Citadel Group has disclosed a 2.33% ownership position in Mural Oncology plc, according to a regulatory filing released Friday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds 403,916 shares representing a long position in the biopharmaceutical company, alongside a short position of 212,823 shares, equivalent to 1.22% of outstanding stock.
The filing details that Citadel’s position includes 375,816 directly owned shares and additional exposure through stock-settled derivatives. The disclosure also documents multiple transactions conducted on August 21, with Citadel both purchasing and selling Mural Oncology shares at prices ranging from $2.07 to $2.09 per share.
The largest single transaction reported was a sale of 51,309 shares at $2.07 per share.
Citadel’s options positions include various put and call contracts with strike prices between $2.50 and $7.50, expiring between September 2025 and January 2027.
Irish regulations require investors to disclose positions representing 1% or more of a company’s securities during takeover situations, though the filing does not specify whether Mural Oncology is currently involved in any acquisition discussions.
Mural Oncology, listed in Ireland with common stock trading under ISIN IE000LK2BOB4, focuses on cancer therapeutics development.
The information was disclosed through a Form 8.3 filing with the Irish Takeover Panel, which mandates transparency for significant shareholders during potential takeover periods.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.